Recombinant human thrombopoietin in myelosuppressive chemotherapy.
Recombinant human thrombopoietin (rhTPO) is a full-length glycosylated molecule that has been under evaluation in the setting of chemotherapy-induced myelosuppression. It has been shown to be a potent stimulator of platelet production in cancer patients when administered prior to chemotherapy. The peak platelet response to a single dose of rhTPO is observed around day 12, and is accompanied by a significant increase in the number of mature megakaryocytes in bone marrow. Consistent with this biologic effect, rhTPO administered postchemotherapy has been shown to be effective in attenuating severe thrombocytopenia induced by carboplatin, which produces a late platelet nadir. Early clinical experience with a regimen that produces an early nadir, however, such as AI (doxorubicin [Adriamycin] and ifosfamide [Ifex]), suggests that administration of rhTPO both prior to and following chemotherapy might be important to reduce thrombocytopenia severity. Treatment with rhTPO in these clinical trials has been well tolerated with a favorable safety profile. Randomized clinical trials have been initiated to determine further the importance of schedule in the prevention and treatment of severe thrombocytopenia in cancer patients.
Vadhan-Raj
S
S
Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D024221:Antineoplastic Protocols; D001853:Bone Marrow / Q000187:drug effects*; D016190:Carboplatin / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*; D013926:Thrombopoietin / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D013926:Thrombopoietin; D016190:Carboplatin